Sensorion 

Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France. It engages in developing USHER-GT, a gene therapy development program to restore inner ear function for patients suffering from usher syndrome Type 1; OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. The company's pipeline includes various products in development stage for restoring, treating, and preventing inner ear related disorders. Sensorion SA has a collaboration agreement with Institut Pasteur for gene therapy program to restore auditory functions; and a strategic collaboration with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. The company was founded in 2009 and is headquartered in Montpellier, France.